This article is more than 5 years old. Information may no longer be current.

Wounded Warrior partnership aims to improve PTSD, TBI diagnosis

The Wounded Warrior Project and Cohen Veterans Bioscience recently announced the Research Alliance for PTSD/TBI Innovation and Discovery Diagnostics, a shared initiative to improve diagnosis and treatment of PTSD and traumatic brain injury.

“Identifying biomarkers is an important step in care for PTSD and [traumatic brain injury (TBI)],” Mike Richardson, vice president of mental health and independence services at Wounded Warrior Project, said in a press release. “We can better target treatment to individual patients and see improved results.”

The collaboration between Research Alliance for PTSD/TBI Innovation and Discovery Diagnostics (RAPID-Dx) and Warrior Care Network aims to expand research on biomarkers, and as a result improve the diagnosis and treatment of PTSD and TBI.

“RAPID-Dx will provide vital information for the precision treatment of patients with PTSD and TBI,” Magali Haas, MD, PhD, CEO of Cohen Veterans Bioscience, said in the release. “This partnership represents a best-in-class approach to helping the thousands of veterans in need, as well as others affected by these debilitating injuries.”

For more information:

To learn more about the Wounded Warrior Project, visit http://newsroom.woundedwarriorproject.org/about-us.

To support and learn about research from Cohen Veterans Bioscience, visit www.cohenveteransbioscience.org.